Real-world-data on Ofatumumab as First-line Treatment in Early RMS (AIOLOS study) (P7-1.013)

The non-interventional study (NIS) AIOLOS evaluates ofatumumab, interferon β1 (IFN-β1) or glatiramer acetate (GA) in treatment-naïve RMS patients who do not meet the highly-active disease criteria in daily clinical routine in Germany.

Authors

Steffen Pfeuffer (ORCID: https://orcid.org/0000-0001-5171-4845)
Gereon Nelles
Carola Wagner

Institutions

Universitätsklinikum Gießen und Marburg (DE)
Novartis (France) (FR)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000211109
Citations: 1
Primary Topic: Myasthenia Gravis and Thymoma
Type: article
Field-Weighted Citation Impact: 1.39

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Real-world-data on Ofatumumab as First-line Treatment in Early RMS (AIOLOS study) (P7-1.013)

Steffen Pfeuffer, Gereon Nelles, Carola Wagner

Apr 7, 2025

1 citations

Neurology

Myasthenia Gravis and Thymoma

1.39

article

Real-world-data on Ofatumumab as First-line Treatment in Early RMS (AIOLOS study) (P7-1.013)

Steffen Pfeuffer, Gereon Nelles, Carola Wagner

April 7, 2025article en

1 citations

Abstract

NeurologyVol. 104(7_Supplement_1)

Universitätsklinikum Gießen und Marburg (DE), Novartis (France) (FR)

Zero hunger

Openalex Percentile: Top 22%

Myasthenia Gravis and Thymoma

1.39

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.